Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor
- PMID: 9816232
Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor
Abstract
DNA-damaging agents arrest cell cycle progression at either G1 or G2. A variety of agents such as caffeine have been shown to abrogate the DNA damage-dependent G2 checkpoint and enhance cytotoxicity. Unfortunately, this strategy has not enhanced therapeutic activity because adequate concentrations of these modulators are not tolerated in vivo. Here, using Chinese hamster ovary cell lines, we show that the potent protein kinase inhibitor 7-hydroxy-staurosporine (UCN-01) abrogates the G2 arrest induced by the DNA-damaging agent cisplatin. UCN-01 not only was effective at inducing mitosis when added to G2-arrested cells but also prevented cells from arresting in G2 when added to S-phase cells. Furthermore, UCN-01 did not cause premature mitosis of S-phase cells; rather, the cells progressed to G2 before undergoing mitosis. These effects were observed at noncytotoxic concentrations of UCN-01 that alone had no effect on cell cycle passage. Furthermore, the same concentrations of UCN-01 that resulted in abrogation of the cisplatin-induced G2 arrest also enhanced cisplatin-induced cytotoxicity, as determined by a colony formation assay. UCN-01 enhanced cisplatin cytotoxicity up to 60-fold and reduced by 3-fold the concentration of cisplatin required to kill 90% of the cells. The concentrations of UCN-01 required for this enhancement have been shown to be well tolerated in animal models, suggesting that this combination may represent an effective strategy for enhancing cisplatin-based chemotherapeutic regimens.
Similar articles
-
7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells.Cell Growth Differ. 1997 Jul;8(7):779-88. Cell Growth Differ. 1997. PMID: 9218872
-
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.J Natl Cancer Inst. 1996 Jul 17;88(14):956-65. doi: 10.1093/jnci/88.14.956. J Natl Cancer Inst. 1996. PMID: 8667426
-
Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines.Biochem Pharmacol. 1999 Dec 1;58(11):1713-21. doi: 10.1016/s0006-2952(99)00258-0. Biochem Pharmacol. 1999. PMID: 10571245
-
UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century?Anticancer Drug Des. 2000 Feb;15(1):43-52. Anticancer Drug Des. 2000. PMID: 10888035 Review.
-
[Cell cycle regulation after exposure to ionizing radiation].Bull Cancer. 1999 Apr;86(4):345-57. Bull Cancer. 1999. PMID: 10341340 Review. French.
Cited by
-
UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA.Jpn J Cancer Res. 2000 Nov;91(11):1192-8. doi: 10.1111/j.1349-7006.2000.tb00904.x. Jpn J Cancer Res. 2000. PMID: 11092986 Free PMC article.
-
Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest.Invest New Drugs. 2011 Aug;29(4):627-36. doi: 10.1007/s10637-010-9401-y. Epub 2010 Mar 2. Invest New Drugs. 2011. PMID: 20195699
-
Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage.Oncogene. 2020 Feb;39(7):1389-1401. doi: 10.1038/s41388-019-1079-9. Epub 2019 Oct 28. Oncogene. 2020. PMID: 31659257 Free PMC article. Review.
-
Protein kinase C targeting in antineoplastic treatment strategies.Invest New Drugs. 1999;17(3):227-40. doi: 10.1023/a:1006328303451. Invest New Drugs. 1999. PMID: 10665476 Review.
-
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.Mol Cancer Ther. 2015 Jan;14(1):174-82. doi: 10.1158/1535-7163.MCT-14-0622-T. Epub 2014 Oct 27. Mol Cancer Ther. 2015. PMID: 25349305 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources